Abbott, Reckitt face trial over premature baby formula amid alarm from doctors
Corrects title of Jonathan Davis in paragraph 9, to Chief of Newborn Medicine at Tufts Medical Center
Doctors fear losing access to essential formulas for premature babies
Plaintiffs argue companies failed to warn about NEC risk from cow's milk-based formula
By Brendan Pierson
Sept 30 (Reuters) -A Missouri mother and her lawyers this week will aim to convince a jury that Abbott ABT.N, Reckitt's RKT.L Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.
The closely watched trial in St. Louis, Missouri state court, which begins with jury selection on Monday, is part of sprawling litigation that has already resulted in verdicts of $60 million against Reckitt and $495 million against Abbott. Close to 1,000 similar cases are still pending nationwide.
Plaintiffs argue that giving cow's milk-based formula to premature babies - especially the smallest ones, born weighing less than about 1,500 grams or about three pounds - greatly increases their risk of developing necrotizing enterocolitis (NEC). That condition has an estimated fatality rate of more than 20%. They also say the companies had a legal responsibility to warn about that risk, but failed to do so.
Both companies said in statements that the lawsuit's claims are not supported by evidence and that their products are essential for premature babies.
St. Louis Children's did not respond to a request for comment on the litigation.
Large verdicts in the two cases that have so far gone to trial have raised alarm among doctors who fear losing access to products they depend on to feed babies.
Abbott and Reckitt are the only companies selling the formulas at issue, which are specialized products used in newborn intensive care units. In a July investor call, Abbott CEO Robert Ford suggested that they might become unavailable because of the litigation. Reckitt also said it was considering "strategic options" for its formula division.
The products for premature babies are not big sellers, bringing Abbott only about $9 million and Reckitt less than $1 million annually, according to company spokespersons.
"I would say there's a genuine panic," said Jonathan Davis, who is Chief of Newborn Medicine at Tufts Medical Center in Boston.
Doctors say the benefits of breast milk for premature babies on a wide range of measures – including lower rates of NEC – have been known for years, and are reflected in hospital feeding practices. But, they say, formula remains vital to feed babies when the mother's or donated breast milk is unavailable or insufficient.
"I would love if every mother could give me breast milk. They can't," said Jill Maron, chief of pediatrics at Women & Infants Hospital in Providence, Rhode Island. "If I don't have access to these products, babies will die."
'MESSAGE OF FEAR'
Tor Hoerman, a lawyer who represents the plaintiff who won the $495 million verdict and others, said doctors are responding to a "message of fear" pushed by the manufacturers, who were unnecessarily suggesting that the products might be withdrawn.
"Nobody is requesting that the product be pulled from the market," Hoerman said. Instead, he said, the companies "could put a simple warning about risk" on the formulas' labels.
At the upcoming trial, plaintiff Elizabeth Whitfield will urge the jury to find that the companies and the hospital were negligent under Missouri law. She says her son, who was born at less than 28 weeks in August 2017, developed NEC the following month as a result of being fed formula and required surgery to remove part of his intestine.
Whitfield's son, like many NEC survivors who have surgery, "continues to suffer from permanent and severe injuries," according to the lawsuit.
The lawsuit and others like it are separate from cases over allegedly contaminated formula from an Abbott factory in Michigan. There are no allegations that the premature baby formula was contaminated.
The science around NEC, breast milk and formula feeding remains unsettled.
A recent report from a U.S. National Institutes of Health working group said that current evidence "supports the hypothesis that it is the absence of human milk – rather than the exposure to formula – that is associated with an increase in the risk of NEC."
The manufacturers say that a label warning that formula can cause NEC would be unsupported. And because doctors are already aware of the research, they say, a label would not change anything.
Several neonatologists interviewed by Reuters said they worried that a warning label could make parents believe formula was unsafe even when it was the best available option.
The NEC Society, a patient-led organization devoted to fighting the disease, has said that formula is sometimes necessary and that lawsuits are not part of its strategy.
"What I would love for everyone to focus on is how we increase equitable access to mother's milk and pasteurized donor milk," said NEC Society Director Jennifer Canvasser, who founded the organization after losing her own son to the disease.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Anna Driver
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
